The Powerhouse for Anti-infectives

2022-04-08

AiCuris nominates Madam Therapeutics with its innovative peptide approach to fight AMR as the first winner of the AiCubator Resident Status in 2022, a corporate innovation accelerator initiative at BIOCOM AMR Conference 2022

In its second year an innovative artificial intelligence-based approach to fight antimicrobial resistance with dual-acting antimicrobial and antibiofilm peptides from Madam Therapeutics was selected to join the AiCubator initiative as the first new Resident in 2022. AiCubator” was launched by AiCuris mid-2020 to provide long-term support for early but promising research projects in the field of anti-infectives

Read more

2022-03-03

AiCuris erhält NRW-Förderung von insgesamt EUR 5,9 Mio. für die Entwicklung seines Corona-Virus-Programms zur Vorbeugung schwerer Symptome bei SARS-CoV-2-Infektionen

AiCuris receives NRW funding of EUR 5.9 million for the development of its corona virus program to prevent severe symptoms of SARS-CoV-2 infections NRW Economics and Innovation Minister Prof. Andreas Pinkwart visited AiCuris Anti-infective Cures AG with good news. Funding of EUR 5.9 million from the Ministry of Economics, Innovation, Digitization and Energy of the State of North Rhine-Westphalia is intended to advance the development of AiCuris' immune modulator AIC649 for the treatment of COVID-19 patients. “The keyword is “pandemic preparedness”. Our drug has the potential to form a protective wall - also against future viruses," said AiCuris CEO Holger Zimmermann. (press release only in German)

Read more

2022-02-09

AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M for a direct-acting RNA-based therapy against BK Virus

AiCuris and Hybridize Therapeutics enter worldwide license agreement for a direct-acting RNA-based therapy against BK Virus. “This exciting novel approach further strengthens our anti-infective pipeline and builds on our strong track record in the field of infectious diseases. If shown to be safe and effective, it could be a true game changer in transplantation medicine with the potential to prevent kidney transplant patients from developing graft rejection and organ loss due to BKV,” said AiCuris CEO Holger Zimmermann.

Read more

2021-10-22

AiCuris announces expansion of its collaboration with Lysando with a focus on diabetic foot infections

AiCuris Anti-infective Cures AG, a leading company in the discovery and development of drugs against infectious diseases, and the biotechnology company Lysando AG with its Regensburg-based subsidiary Lysando GmbH, today announced the expansion of their existing long-term collaboration for the development and optimization of Artilysin®-based drug candidates for the topical treatment of infected, chronic wounds such as diabetic foot infections.

Read more

2021-10-07

AiCuris announces opening of second round of AiCubator corporate innovation accelerator initiative to propel anti-infective drug development

AiCuris Anti-infective Cures AG, a leading company in the discovery and development of drugs against infectious diseases, today announced the opening of the second round of its AiCubator corporate innovation accelerator initiative.

Read more

2021-09-20

AiCuris starts pilot trial with proprietary immunomodulator AIC649, a unique therapy to prevent severe symptoms in SARS-CoV-2 infections

Start of a pilot study with immunomodulator AIC649 for treatment of asymptomatic or mildly symptomatic COVID-19-patients to prevent more severe symptoms including respiratory failure that may develop with progression of the disease.

Read more

2021-09-17

AiCuris befürwortet und unterstützt die Nationale Allianz für Pandemie-Therapeutika (NA-PATH)

NA-PATH ist eine Initiative des Helmholtz-Zentrums für Infektionsforschung (HZI) und des Deutschen Zentrums für Infektionsforschung (DZIF), die einen Sektor-übergreifenden Ansatz vorschlägt, um auf zukünftige Pandemien durch virale Erreger vorbereitet zu sein.

Read more

2021-07-08

AiCuris starts its first pivotal clinical phase 3 trial with pritelivir for the treatment of herpes simplex virus infections in immunocompromised subjects based on efficacy and safety data from a phase 2 trial

Start of pivotal phase 3 development with its proprietary lead compound pritelivir, a novel helicase-primase inhibitor, following encouraging phase 2 interim results achieved in the phase 2 part of its clinical phase 2/3 trial, PRIOH-1.

Read more

2021-05-25

AiCuris AG Announces Dr. Stefan Oschmann, Former Merck CEO, to Chair the AiCuris Supervisory Board

The Supervisory Board appointed Dr. Stefan Oschmann as Chairman. He succeeds Helmut Jeggle, Chief Executive Officer of Salvia GmbH, who stepped down as planned from his role as Interim-Chairman of the initial Supervisory Board of AiCuris AG

Read more